Spatiotemporal Mapping of Brain Organisation Following the Administration of 2C-B and Psilocybin

Why It Matters

Understanding how 2C‑B modulates brain networks provides insight into designing next‑generation psychedelics with tailored therapeutic profiles, potentially offering milder side‑effects while retaining therapeutic mechanisms. The pharmacology‑driven connectivity signatures also help link specific receptor targets to clinical outcomes.

Key Takeaways

• 2C‑B reduces intranetwork connectivity similar to psilocybin
• 2C‑B shows less between‑network dFC reduction than psilocybin
• Both increase global connectivity and brain signal complexity
• Effects align with 5‑HT2A, 5‑HT1A, and DAT receptor densities
• Subjective experience tracks transmodal cortex decoupling

Pulse Analysis

The resurgence of psychedelic‑assisted therapy has sparked intense interest in compounds that can replicate the therapeutic benefits of classic agents such as psilocybin while minimizing adverse experiences. Phenethylamine 2C‑B, long popular in recreational circles, offers a distinct receptor profile that includes higher selectivity for 5‑HT2A and measurable affinity for monoamine transporters. Prior to this work, its neural impact remained undocumented, leaving a gap in the translational pipeline that bridges pharmacology with functional brain dynamics. By leveraging ultra‑high‑field 7 Tesla resting‑state fMRI, researchers were able to capture fine‑grained spatiotemporal changes induced by a controlled 20 mg dose of 2C‑B.

The imaging results revealed a pattern of network desegregation that mirrors classic psychedelics: static functional connectivity within visual and default‑mode subnetworks declined, while cross‑network links, especially between frontoparietal and salience systems, strengthened. Global connectivity rose across most cortical regions, and entropy‑based metrics such as sample entropy and Lempel‑Ziv complexity showed significant elevations, indicating richer spontaneous BOLD fluctuations. Notably, 2C‑B produced a milder drop in dynamic connectivity variability than psilocybin and uniquely boosted transmodal static connectivity. Spatial correlation with PET‑derived receptor maps linked these effects to 5‑HT2A, 5‑HT1A, and dopamine transporter densities, underscoring the role of secondary pharmacology.

These findings have practical implications for drug development. Demonstrating that a non‑tryptamine psychedelic can elicit core neural signatures of therapeutic psychedelia suggests that receptor‑targeted design may yield compounds with comparable efficacy but reduced dysphoria or ego‑dissolution. Moreover, the identified connectivity‑experience relationships provide candidate biomarkers for dose‑finding and patient stratification in future clinical trials. As the field moves toward precision psychedelic medicine, integrating multimodal imaging with molecular profiling, as exemplified by this study, will be essential for translating nuanced pharmacodynamic differences into measurable clinical outcomes.